Business Context and Reporting Period
This Form 8-K, dated October 20, 2014, reports a material definitive agreement entered into by Platform Specialty Products Corporation (the "Registrant"). The filing discloses the execution of a Share Purchase Agreement to acquire Arysta LifeScience Limited, a global provider of crop solutions, from Nalozo S.à.r.l.
Key Financial Metrics and Transaction Structure
The total consideration for the acquisition is approximately $3.51 billion, structured as follows:
- Cash Component: Approximately $2.91 billion, subject to working capital and other adjustments.
- Equity Component: $600 million in new Series B convertible preferred stock.
The Series B Convertible Preferred Stock has a liquidation preference of $1,000 per share and a conversion price of $27.14 per share of common stock. The filing does not provide specific revenue, profit, cash flow, or margin data for the Registrant or the target, as this is a transaction announcement rather than a periodic financial report.
Material Changes and Funding
The acquisition represents a significant expansion of the Registrant's business into agrochemical and biological products. The transaction is expected to be funded through a combination of cash on hand, debt, seller financing, and possible other financings. The filing does not provide specific details on the Registrant's current debt levels or liquidity position prior to this transaction.
Guidance, Outlook, and Risks
Closing Timeline: The transaction is expected to close in the first quarter of 2015.
Conditions Precedent: Closing is subject to customary conditions, including the expiration of the Hart-Scott-Rodino waiting period and approvals from U.S. and non-U.S. government and antitrust authorities.
Termination Provisions: The agreement may be terminated if not consummated by June 1, 2015, extendable to August 3, 2015, if regulatory approvals are pending. Neither party is responsible for a termination fee.
Covenants: The Seller has agreed to operate Arysta in the ordinary course of business and refrain from material investments, indebtedness, or asset dispositions without consent. The Registrant has covenanted not to make acquisitions that could delay regulatory approval or financing, and not to declare dividends (except on Series A preferred stock) or issue senior equity.
Investor Verification Checklist
- Verify the final closing date and whether all regulatory approvals (Hart-Scott-Rodino and international) were obtained.
- Confirm the final purchase price after working capital and other adjustments.
- Review the specific terms of the debt financing and seller financing utilized to fund the $2.91 billion cash portion.
- Assess the dilution impact of the $600 million Series B convertible preferred stock on existing common shareholders.
- Monitor for any termination of the agreement if the June 1, 2015, or August 3, 2015, deadlines are not met.